Karagoz Ergenekon, Selek Mehmet Burak, Tanoglu Alpaslan, Hatipoglu Mustafa, Ulçay Asim, Turhan Vedat
Gata Haydarpasa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey.
Gata Haydarpasa Training Hospital, Department of Medical Microbiology, Istanbul, Turkey.
Infez Med. 2016 Dec 1;24(4):287-292.
Quantitative hepatitis B surface antigen (HBsAg) is a valuable tool in hepatitis B virus (HBV) disease diagnosis and management for evaluating the effectiveness of antiviral therapy. The aim of the current research was to compare the performances of the Elecsys HBsAg II and Abbott Architect HBsAg assays in chronic hepatitis B (CHB) patients. Between May 2014 and December 2014, 72 CHBs were tested using Abbott Architect HBsAg QT and Roche Elecsys HBsAg II assay. After transformation to log (10) IU/mL, the results of the two assays were compared using the interclass correlation test, the Pearson correlation test and Bland-Altman analyses. We also analyzed all the parameters in on-treatment patients and naive patients with Pearson correlation test. There was a significant overall correlation between the Elecsys and Architect assays. We also analyzed all the parameters in naive and on-treatment patients. There was a significantly good correlation between the two assays in untreated patients and on-treatment patients. In this study, there was a significant correlation between the results of the Elecsys HBsAg II and Abbott Architect HBsAg assays in the overall and naive/on-treatment CHB patients. Additionally, we found that mean HBsAg levels resulting from the Architect assay were higher than those obtained by Elecsys assay.
定量乙肝表面抗原（HBsAg）是评估抗病毒治疗效果的乙肝病毒（HBV）疾病诊断和管理中的一项重要工具。本研究旨在比较Elecsys HBsAg II和雅培Architect HBsAg检测方法在慢性乙型肝炎（CHB）患者中的表现。2014年5月至2014年12月期间，对72例CHB患者采用雅培Architect HBsAg QT和罗氏Elecsys HBsAg II检测方法进行检测。转换为log(10) IU/mL后，使用组内相关检验、Pearson相关检验和Bland-Altman分析对两种检测方法的结果进行比较。我们还使用Pearson相关检验分析了正在接受治疗的患者和初治患者的所有参数。Elecsys和Architect检测方法之间存在显著的总体相关性。我们还分析了初治患者和正在接受治疗的患者的所有参数。两种检测方法在未治疗患者和正在接受治疗的患者中具有显著的良好相关性。在本研究中，Elecsys HBsAg II和雅培Architect HBsAg检测方法在总体CHB患者以及初治/正在接受治疗的CHB患者中的结果存在显著相关性。此外，我们发现Architect检测方法得出的HBsAg平均水平高于Elecsys检测方法得出的水平。
